Pepinemab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Pepinemab
Accession Number
DB15155
Type
Biotech
Groups
Investigational
Description

Pepinemab is under investigation in clinical trial NCT03769155 (VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma).

Synonyms
  • MOAB VX15/2503
  • VX15/2503
Categories
Not Available
UNII
BPZ4A29SYE
CAS number
2097151-87-4

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentDisseminated Sclerosis1
1CompletedTreatmentTumors, Solid1
1RecruitingTreatmentPathologic Stage IIIB Cutaneous Melanoma AJCC v8 / Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 / Pathologic Stage IIID Cutaneous Melanoma AJCC v81
1RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1, 2Not Yet RecruitingTreatmentRecurrent Malignant Solid Neoplasm / Recurrent Osteosarcoma / Refractory Malignant Solid Neoplasm1
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2RecruitingTreatmentRecurrent Malignant Solid Neoplasm / Recurrent Osteosarcoma / Refractory Malignant Solid Neoplasm / Refractory Osteosarcoma1
2Active Not RecruitingTreatmentHuntington's Disease (HD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:54 / Updated on September 02, 2019 20:28